Submitting an appeal is easy. Submitting an appeal that actually addresses why a claim was denied is a different skill.

In this episode of Revenue RX, we break down the pharmacy appeals process from both a reimbursement and financial perspective. We start with one of the most important decisions: determining whether a denial requires a corrected claim, reconsideration, or formal appeal.

We discuss why the denial code should drive the strategy, how to match documentation to the payer’s specific reason for denial, and what belongs in a strong appeal packet. We also walk through a medical necessity appeal example, including how payer coverage policies, clinical documentation, diagnosis information, and supporting evidence can turn a generic appeal into a defensible case.

The goal isn’t to build the thickest appeal packet. It’s to identify the root cause, choose the right pathway, submit evidence that answers the payer’s question, and do it before the deadline.

Takeaways

• Determine whether the denial needs a corrected claim, reconsideration, or formal appeal before escalating.
• Start with the claim adjustment reason code and investigate the workflow failure behind it.
• Match supporting documentation directly to the payer’s stated denial reason.
• Medical necessity appeals should demonstrate how the patient met coverage criteria or why an exception was clinically justified.
• Include complete claim and patient identifiers to prevent avoidable delays or returns.
• Track appeal deadlines at the individual claim level with a clear owner and next action.
• Explore manufacturer replacement programs when appropriate for qualifying high-cost medications.
• Measure appeal performance using overturn rate, dollars recovered, and the percentage of eligible denials appealed.
• Strong appeals are focused, evidence-based, timely, and built around the payer’s actual question.

Chapters

00:02 Understanding Appeals in Pharmacy and Finance
00:54 Corrected Claim, Reconsideration, or Appeal?
02:17 Start With the Denial Code
04:27 Match the Evidence to the Denial
05:19 Building a Strong Appeal Packet
06:15 Building a Strong Medical Necessity Appeal
08:21 Appeal Deadlines Matter
09:27 Manufacturer Replacement Programs
10:13 Measuring Appeal Performance
11:04 What Makes an Appeal Get Paid
11:54 Disclaimer

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Fixing a denied claim is not the same as fixing the problem that caused it.

In this episode of Revenue RX, we explore how pharmacy revenue cycle teams can move beyond individual claim resolution and build a closed-loop process that prevents recurring denials, underpayments, and reimbursement gaps. We break down how to identify root causes, route issues to the right operational owners, correct upstream workflows and system builds, and turn payer-specific discoveries into institutional knowledge.

We also discuss why corrective actions need clear ownership, deadlines, and measurable outcomes—and why successful revenue cycle programs should track not only recovered revenue, but also the revenue losses prevented when claims are paid correctly the first time.

Takeaways

• Resolving a claim recovers revenue; correcting the underlying workflow protects future revenue.
• Categorizing root causes helps identify the team responsible for fixing the problem.
• Recurring authorization, documentation, coding, NDC, unit, modifier, and system-build issues should be addressed upstream.
• Successful appeals can reveal opportunities for prevention when the same denial repeatedly occurs.
• Education is most effective when teams understand exactly what needs to change and why it affects reimbursement.
• Every corrective action should have an owner, deadline, and defined method for measuring results.
• Measurement should focus on the specific denial, underpayment, documentation issue, or workflow that was changed.
• Prevented revenue loss may never appear on a recovery report, but it can represent some of the most valuable work performed by a mature revenue cycle program.
• A closed-loop revenue cycle becomes a learning system in which every denial, underpayment, and successful appeal improves future claims.

Chapters

00:00 Closing the Loop in Pharmacy Revenue Cycle
01:21 Find the Root Cause
03:40 Fix the Upstream Workflow
04:05 Correct the System Build
05:51 Educate the Right Teams
07:26 Assign Owners and Deadlines
08:26 Measure the Fix
09:21 Recovered vs. Prevented Revenue
10:28 Build a Learning System
11:23 Disclaimer

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Denial rate alone does not tell the full story of revenue cycle performance. Before a claim can be fixed, teams need to correctly diagnose what actually happened: Was it rejected before adjudication, denied after adjudication, underpaid, paid at zero, or only partially paid?

In this episode of Revenue RX, we break down the operational differences between rejections and denials and explain how Claim Adjustment Reason Codes (CARCs), Remittance Advice Remark Codes (RARCs), and group codes work together to provide a clearer picture of claim outcomes.

We also explore why clinical and administrative denials require completely different skill sets and workflows, using examples such as CARC 50 for medical necessity, CARC 197 for authorization requirements, and CARC 16 paired with RARCs that identify specific billing or documentation issues.

Takeaways

• A rejection occurs before adjudication, while a denial occurs after the payer processes the claim and makes a payment determination.
• Rejected claims may not contain CARCs or RARCs because they never reached adjudication.
• CARCs explain why a payment was adjusted, while RARCs provide additional context about the adjustment.
• Group codes such as CO, PR, and OA help identify financial responsibility for adjusted amounts.
• A CARC does not automatically represent a denial; some adjustments are expected contractual or patient-responsibility outcomes.
• Clinical denials such as medical necessity or experimental and investigational determinations often require pharmacist, nurse, or prescriber involvement.
• Administrative denials such as missing prior authorization require workflow and operational fixes rather than clinical appeals.
• CARC 16 demonstrates why CARCs should be interpreted alongside RARCs to identify the actual root cause.
• Underpayments can create significant revenue leakage without generating a denial or work queue entry.
• Zero-pay and partial-pay claims must be evaluated against reason codes and contract terms before determining whether payment is correct.
• Rejections, administrative denials, clinical denials, and underpayments should not all be routed through the same workflow.
• Denial rate should be evaluated alongside rejection rates, underpayment variance, and zero-pay findings for a more complete view of revenue cycle performance.

Chapters

00:00 Introduction
00:38 Rejections vs. Denials
02:16 Claim Adjustment Reason Codes (CARCs), Remittance Advice Remark Codes (RARCs), & Group Codes
03:36 Clinical Denials vs. Administrative Denials
07:22 Underpayments
08:44 Delegate Appropriately
10:43 Disclaimer

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

In this episode of Revenue RX, the focus is on the key performance indicators that matter most across the pharmacy revenue cycle. From front-end authorization and financial clearance to charge capture, denials, underpayments, write-offs, and financial performance, the discussion breaks down how teams can use KPIs to identify risk and drive action.

The episode also explains why not every metric deserves a place on a scorecard. A meaningful KPI should influence a decision, trigger an investigation, or lead to a workflow change. By connecting operational measures with financial outcomes, pharmacy revenue cycle teams can better protect patient access, reimbursement, cash, and margin.

Takeaways

• A KPI should be connected to a priority and lead to action, not simply appear on a dashboard.
• Front-end KPIs such as pre-service authorization rate, authorization turnaround time, scheduled service clearance, and treatment delays can serve as leading indicators of future denials.
• Mid-cycle KPIs help identify problems with charge capture, reconciliation, billing units, modifiers, and clean claims.
• Back-end performance should be evaluated using both denial frequency and financial exposure, including denial dollars, preventable denials, recovery, aging, underpayments, and terminal write-offs.
• Negative-margin administrations, 340B capture, and cost to collect can provide additional insight into financial performance.
• Segmenting KPIs by payer, medication, drug class, location, and site of care can reveal problems that aggregated results may hide.
• Every KPI should have an owner responsible for investigating changes and coordinating corrective action.
• Operational KPIs show teams what needs to be fixed, while financial KPIs help explain to leadership why fixing it matters.

Chapters

01:46 Front-end KPIs
04:01 Mid-cycle KPIs
06:24 Back-end KPIs
10:51 Financial KPIs
15:50 Disclaimer

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

CMS’s proposed CY 2027 340B policy could change more than reimbursement. It could change how acquisition decisions, billing modifiers, and drug margin interact.

In this episode of Revenue RX, we break down the proposed return of the JG modifier as a payment-triggering modifier, the continued use of TB for certain exempt 340B drugs and providers, and CMS’s proposed new XX modifier for drugs acquired outside the 340B program.

Takeaways

• CMS is proposing to pay certain 340B-acquired drugs at ASP minus 33.4% beginning in CY 2027.
• JG would identify applicable 340B-acquired drugs and trigger the proposed payment adjustment.
• TB would continue to identify certain 340B drugs and providers that are exempt from the proposed payment reduction.
• CMS is proposing a new placeholder modifier, XX, to affirmatively identify separately payable drugs acquired outside the 340B program.
• Hospitals should begin evaluating acquisition-status data, JG and TB logic, proposed non-340B workflows, and drug-level margin exposure.
• The policy remains proposed, and comments are due August 31, 2026.

Chapters

01:33 How We Got Here
02:34 JG Modifier
03:21 TB Modifier
04:08 XX Modifier
05:07 340B vs. WAC
10:14 What Hospitals Should Do Now
10:54 Disclaimer

References

• CMS CY 2027 Hospital Outpatient Prospective Payment System proposed rule, CMS-1850-P
• Docket CMS-2026-2344
• American Hospital Association v. Becerra
• CMS Outpatient Drug Acquisition Cost Survey, ODACS

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

This episode breaks down how to build an effective team around a complex healthcare function, from identifying the work that needs to be done to determining the right roles, reporting structure, and timing for new hires. The discussion explores how to map responsibilities, avoid common organizational mistakes, and create a team structure that supports both operational execution and long-term growth.

Takeaways

• Start by mapping the functions and responsibilities the team needs to own before deciding on titles or headcount.
• Define clear roles so accountability does not become fragmented across departments.
• Build the team around organizational needs, workload, and strategic priorities rather than a one-size-fits-all structure.
• Reporting structure matters and should support collaboration, visibility, and appropriate decision-making authority.
• Avoid adding roles without first clarifying ownership, workflows, and expectations.
• Use workload, complexity, organizational growth, and capability gaps to help determine when additional hiring is justified.

Chapters

00:32 Why This Team Matters
01:58 Map the Functions
03:21 Core Team Roles
06:09 How to Build the Team
07:26 Where Should It Report?
08:54 Common Mistakes
10:29 When to Hire
12:51 Disclaimer

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Pass-through status is not a one-time CMS classification. It is a constantly moving pipeline, with new drugs entering protected payment status while others transition into standard OPPS reimbursement.

In this episode of Revenue RX, we use the July 1, 2026 OPPS updates as a real-world case study to break down what changed and what pharmacy revenue cycle teams should be watching.

We cover newly coded drugs, biologics, and radiopharmaceuticals entering status indicator G, biosimilars receiving their own pass-through status, products exiting pass-through and moving to status indicator K, and retroactive status indicator changes that may require us to revisit previously submitted claims.

Most importantly, we focus on the operational side of pass-through management: building new products into the charge description master promptly, monitoring high-volume drugs as they exit pass-through, reviewing quarterly CMS updates, and creating workflows to identify retroactive reimbursement opportunities.

Takeaways

• Pass-through status indicator G generally provides a two- to three-year protected payment window under OPPS while CMS collects hospital cost and utilization data.

• Biosimilars may qualify for their own pass-through periods even when the underlying molecule is already established in the market.

• Drugs exiting pass-through with meaningful organizational utilization should be placed on our margin monitoring list.

• Retroactive status indicator changes may create opportunities for us to reassess previously billed claims and determine whether additional reimbursement is appropriate.

• We should review CMS status indicators quarterly through Addendum B rather than only during annual updates.

• Pharmacy revenue cycle teams should maintain a separate workflow for retroactive status changes and establish reminders to reassess products approaching the end of their pass-through window.

Chapters

00:00 The Pass-Through Pipeline
01:02 Quick Recap: Status Indicator G
01:39 July 2026: New Pass-Through Drugs
02:46 Biosimilars Entering Pass-Through
03:39 Drugs Exiting Pass-Through Status
04:35 Retroactive Status Indicator Changes
05:24 Building a Quarterly Monitoring Process
06:50 Disclaimer

References

CMS Hospital Outpatient Prospective Payment System (OPPS) quarterly updates and Addendum B, July 2026

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Every HCPCS code billed under the Outpatient Prospective Payment System (OPPS) is assigned a status indicator. But what do those letter designations mean for reimbursement?

In this episode of Revenue RX, we explore how CMS uses OPPS status indicators to determine payment methodology for outpatient services, drugs, biologics, and vaccines. Learn the difference between separately payable, packaged, and non-covered services, why status indicators matter for pharmacy reimbursement, and how understanding these payment rules can help prevent costly billing mistakes.

The episode explores key pharmacy-related status indicators, including G, H, K, L, N, and E. It also explains the purpose of pass-through payment, what happens when pass-through status expires, and why losing pass-through does not necessarily mean losing reimbursement. Lubna shares practical memory aids and highlights common operational mistakes involving packaged services, Charge Description Master (CDM) maintenance, and reporting requirements.

Whether you are new to OPPS or looking for a refresher on CMS payment methodology, this episode provides a practical framework for interpreting status indicators with confidence.

Takeaways

• Understand what OPPS status indicators are and how CMS uses them to determine payment methodology.
• Learn the difference between separately payable, packaged, and non-covered services.
• Review the pharmacy-related status indicators G, H, K, L, N, and E.
• Understand the purpose of pass-through payment and why it is temporary.
• Learn what happens when a drug transitions from pass-through to non-pass-through status.
• Recognize that non-pass-through does not automatically mean packaged.
• Avoid common reimbursement mistakes related to status indicator interpretation.
• Understand why packaged services with Status Indicator N should still be reported on claims.
• Learn why maintaining an up-to-date Charge Description Master (CDM) is essential for accurate reimbursement expectations.
• Use simple memory tricks to remember commonly used OPPS status indicators.

Chapters

00:00 Introduction

00:19 What Is a Status Indicator?

01:42 Important Pharmacy Status Indicators

02:57 Pass-Through vs. Non-Pass-Through Payment

04:39 Memory Tricks for Status Indicators

05:30 Common Billing Mistakes to Avoid

06:37 Disclaimer

References

• Medicare Claims Processing Manual, Chapter 4, Hospital Outpatient Prospective Payment System
• Noridian Healthcare Solutions. OPPS Payment Status Indicators. Available at: Noridian OPPS Payment Status Indicators

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

In this episode of Revenue RX, we discuss why the NDC/HCPCS crosswalk serves as the "Rosetta Stone" of pharmacy billing, translating the language of pharmacy (NDCs) into the language of medical billing (HCPCS codes).

• Understand the purpose of the NDC/HCPCS Crosswalk and why it is essential for pharmacy billing.
• Learn why NDC-to-HCPCS relationships are at times many-to-one or one-to-many rather than simple one-to-one mappings.
• Explore real-world crosswalk examples involving prednisone, enoxaparin, normal saline, argatroban, and buprenorphine.
• See how HCPCS billing units are calculated using drugs such as pembrolizumab and rituximab.
• Discover why quarterly CMS crosswalk updates are critical for maintaining an accurate CDM and compliant billing workflows.
• Understand how payer-specific crosswalks can differ from CMS guidance and contribute to claim edits and denials.

Chapters

00:00 Introduction

00:27 The Rosetta Stone of Pharmacy Billing

01:52 Real-World Crosswalk Examples

04:08 Billing Units and Quarterly Updates

06:00 Payer Differences

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Description

CMS has proposed one of the most significant changes to 340B reimbursement since the Supreme Court's 2022 decision in American Hospital Association v. Becerra. In this special episode of Revenue RX, we break down the Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and explain what it could mean for hospitals participating in the 340B Drug Pricing Program.

Whether you work in pharmacy, finance, revenue cycle, compliance, or executive leadership, this episode provides the context and financial perspective needed to begin assessing your organization's exposure.

Takeaways

• CMS has proposed reducing Medicare reimbursement for 340B-acquired drugs to ASP minus 33.4% beginning in CY 2027.
• The proposal follows a new CMS acquisition cost survey intended to address the legal issues identified by the Supreme Court in 2022.
• CMS estimates the proposal would reduce Medicare drug payments by approximately $4.55 billion in the first year.
• CMS also proposes accelerating the OPPS budget neutrality offset from 0.5% to 3% annually, completing the $7.8 billion remedy recovery by 2029.
• Health systems could experience simultaneous impacts to both drug reimbursement and non-drug OPPS payments.
• Organizations should model their financial exposure using current and proposed payment methodologies.
• Comments on the proposed rule are due by August 31, 2026.
• Pharmacy and finance leaders should work together to evaluate multiple budget scenarios until the final rule is released.

Chapters

00:00 CMS Proposes Major 340B Payment Changes

00:57 The History: ASP -22.5%, the Supreme Court, and the Remedy

02:34 The New Proposal: ASP -33.4%

04:02 The Accelerated Clawback and Budget Neutrality

05:02 Financial Implications for Health Systems

05:56 Why the Precedent Matters

06:23 Four Actions to Take Now

08:20 Disclaimer

References

• CMS CY 2027 OPPS Proposed Rule Fact Sheet
• CMS-1850-P Proposed Rule
• CMS Hospital Outpatient PPS
• HRSA 340B Drug Pricing Program

Disclaimer

This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Consult your internal compliance, legal, finance, and revenue cycle teams before making any decisions.